Advertisement
Home »

Response-Directed Treatment Personalization in Stage III Melanoma

Jun 12, 2023

REFERENCES & ADDITIONAL READING

Menzies AM, et al. Nature Medicine. 2021;27:301–309.

Reijers ILM, et al. The impact of response-directed treatment personalization on survival after neoadjuvant checkpoint blockade in stage III melanoma. Comparison of 3-year data from PRADO and OpACIN-neo. Abstract 101. ASCO Annual Meeting 2023, 2–6 June, Chicago.

Reijers ILM, et al. Nat Med. 2022;28:1178–1188.

Rozeman EA, et al. Lancet Oncol. 20219;20:948–960.

Versluis JM, et al. Nature Medicine. 2020;26:475–484.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement